RecruitingNCT06534463

Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)

The Effectiveness and Safety of Different Treatment Modalities in Real-World Clinical Practice Among Chinese Patients with Marginal Zone Lymphoma: a Prospective, Observational, Multi-center Study

Sponsor

Ruijin Hospital

Enrollment

500 participants

Start Date

Aug 2, 2024

Study Type

OBSERVATIONAL

Conditions

Marginal Zone Lymphoma

Summary

This study aims to evaluate real-world treatment modalities and their corresponding effectiveness and safety in Chinese patients with marginal zone lymphoma, while also exploratively analyzing patient characteristics and health-related quality of life.

Eligibility

Min Age: 14 Years

Plain Language Summary

Simplified for easier understanding

This study is a patient registry — meaning it collects information about real-world patients rather than testing a new drug — for Chinese patients diagnosed with marginal zone lymphoma (MZL), a slow-growing type of B-cell lymphoma. The registry will track how patients are treated and how they respond over time, helping doctors better understand the disease and improve future treatment decisions. **You may be eligible if...** - You have been diagnosed with marginal zone lymphoma (MZL) - You meet the treatment indications for MZL (your doctors believe treatment is appropriate) **You may NOT be eligible if...** - Your doctor believes there is any reason you should not participate in this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERAll treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.

The dosage and duration of any drug in this study will be determined by the physician based on local clinical practice and local drug labels. The drugs in this study include, but are not limited to, Obinutuzumab, Rituximab, Bruton tyrosine kinase inhibitors, and Lenalidomide. In this non-interventional study, all treatment drug usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.

Locations(1)

Shanghai Ruijin Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06534463

Related Trials

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716127 locations

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862277 locations

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

NCT0529473129 locations

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

NCT044913701 location

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

NCT065335799 locations